Investor

MFDA Hearing Panel imposes sanctions in the matter of Joel Attis

Retrieved on: 
Friday, November 11, 2022
Mutual Fund Dealers Association, Misconduct, Mid-Atlantic Regional Council on the Ocean (MARCO), Notice, Respondent, Investor, Notice of Hearing, Person, Fine, Amend, Hearing, Renewable energy, Financial adviser, Reason (argument)

TORONTO, Nov. 11, 2022 /CNW/ - The Mutual Fund Dealers Association of Canada ("MFDA") commenced a disciplinary proceeding in respect of Joel Henry Attis (the "Respondent") by Notice of Hearing dated December 18, 2019, as amended on July 12, 2021 ("Amended Notice of Hearing").

Key Points: 
  • TORONTO, Nov. 11, 2022 /CNW/ - The Mutual Fund Dealers Association of Canada ("MFDA") commenced a disciplinary proceeding in respect of Joel Henry Attis (the "Respondent") by Notice of Hearing dated December 18, 2019, as amended on July 12, 2021 ("Amended Notice of Hearing").
  • In its Decision (Misconduct) and Reasons dated July 5, 2022, the Hearing Panel found that the two allegations set out in theAmendedNotice of Hearing against the Respondent had been established.
  • A penalty hearing in this proceeding took place electronically by videoconference on November 10, 2022, before a three-member Hearing Panel of the MFDA's Atlantic Regional Council.
  • Copies of the Decision (Misconduct) and Reasons and the Amended Notice of Hearing are available on the MFDA website at www.mfda.ca .

EQS-News: Stabilus SE: With record revenue in Q4 FY2022, Stabilus achieved annual revenue of €1.1 billion, exceeding the threshold of €1 billion for the first time

Retrieved on: 
Friday, November 11, 2022
CEO, Development, FCF, Distributor, Annual report, Machine industry, WKN, Group, ISIN, ADJ, Investor, EBIT, Mobility, Growth, Pharmaceutical industry, Fine chemical, Video game, Bookkeeping, Asia-Pacific, EMEA

Stabilus SE: With record revenue in Q4 FY2022, Stabilus achieved annual revenue of 1.1 billion, exceeding the threshold of 1 billion for the first time

Key Points: 
  • Stabilus SE: With record revenue in Q4 FY2022, Stabilus achieved annual revenue of 1.1 billion, exceeding the threshold of 1 billion for the first time
    The issuer is solely responsible for the content of this announcement.
  • In the fourth quarter of FY2022, Stabilus increased its revenue by 39.5% year-on-year to 320.3 million (Q4 FY2021: 229.6 million).
  • Thus, revenue in the fourth quarter is also noticeably above the level before the start of the pandemic in 2019.
  • In Asia-Pacific (APAC), the company again recorded above-average revenue growth of 72.7% year-on-year to 259.4 million (FY2021: 150.2 million).

Ghislain Houle, Executive Vice-President and Chief Financial Officer, to Address 2022 Scotiabank Transportation and Industrials Conference on November 15

Retrieved on: 
Friday, November 11, 2022
Webcast, CNI, Transport, GLOBE, TSX, Investor, Conference, CNR, NYSE, Natural Resources, Social responsibility, Oil

MONTREAL, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Ghislain Houle, Executive Vice-President and Chief Financial Officer, of CN (TSX: CNR) (NYSE: CNI), will address the 2022 Scotiabank Transportation and Industrials Conference on November 15, 2022 at 8:00 a.m. Eastern Time (ET).

Key Points: 
  • MONTREAL, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Ghislain Houle, Executive Vice-President and Chief Financial Officer, of CN (TSX: CNR) (NYSE: CNI), will address the 2022 Scotiabank Transportation and Industrials Conference on November 15, 2022 at 8:00 a.m. Eastern Time (ET).
  • CN will provide a live webcast via the Investors section of its website at www.cn.ca/investors .
  • A replay of the webcast will be available following the event.
  • CN is a world-class transportation leader and trade-enabler.

Surmodics Announces SWING Trial 12-Month Data to be Presented at VEITHsymposium on November 16

Retrieved on: 
Friday, November 11, 2022
Medical Devices, Health, Surgery, Clinical Trials, General Health, Pharmaceutical, Aortoiliac occlusive disease, Sale, Company, Annual report, NASDAQ, Disease, Auckland City Hospital, Technology, Cell, DCB, SEC, Safety, Investor, 3rd Floor, Forward-looking statement, MS, Restenosis, Master of Medicine, FRANZCR, AMP, Growth, Amputation, PHD, ONZM, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery, FRACS, Anesthetic, MBBS

The session will be held on Wednesday, November 16, at the 49th Annual Symposium on Vascular and Endovascular Issues (VEITHsymposium) in New York City.

Key Points: 
  • The session will be held on Wednesday, November 16, at the 49th Annual Symposium on Vascular and Endovascular Issues (VEITHsymposium) in New York City.
  • Professor Andrew Holden, MBChB, FRANZCR, EBIR, ONZM, Director of Northern Region Interventional Radiology Service at Auckland City Hospital in Auckland, New Zealand, is also a co-lead investigator for the SWING Trial.
  • Professor Varcoe recently presented SWING Trial 6-month data on October 11 as part of the Amputation Prevention Symposium (AMP) in Lugano, Switzerland.
  • Surmodics is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays.

Leading Philanthropies Commit Half a Billion for an Equitable Energy Transition

Retrieved on: 
Friday, November 11, 2022
CEO, Investment, International Resource Panel, UNEP, Face, Solution, Leadership, Hand, Government, Environment, Investor, Global South, Partnership, Climate change, Renewable energy

SHARM EL-SHEIKH, Egypt, Nov. 11, 2022 /PRNewswire/ -- A coalition of leading climate philanthropies today announced an investment of $500 million over the next three years to accelerate a just and equitable energy transition in low and middle income countries, while boosting sustainable development and creating new economic opportunities.

Key Points: 
  • This catalytic philanthropic support will assist efforts by governments alongside civil society organizations and others that give momentum to new and emerging energy transition plans in the Global South.
  • "The world needs southern leadership to prove that development priorities and climate priorities go hand in hand and build precedents for a truly just and equitable clean energy transition."
  • "This funding is intended to support countries to implement their ambitious, just and equitable clean energy agendas," said Christie Ulman, President of Sequoia Climate Foundation.
  • Another key priority for philanthropies is to scale civil society efforts as they continue to be driving forces for a just transition.

EQS-News: CANCOM: Around 11 percent growth in the third quarter of 2022

Retrieved on: 
Friday, November 11, 2022
Cloud, COO, Investor, Cloud computing, Interim, Revenue stream, Income, ISIN, Organization, Solution, EBITDA, CFO, Company, Frankfurt Stock Exchange, SE, RTÉ Executive Board, CEO, Tax, SDAX, TecDAX, Public sector, ARR, Board of directors, CANCOM, Audit, Video game, Financial adviser, Group, DACH

Interim statement for the third quarter of 2022 confirms published preliminary results of the CANCOM Group.

Key Points: 
  • Interim statement for the third quarter of 2022 confirms published preliminary results of the CANCOM Group.
  • Accordingly, in the third quarter of 2022 the CANCOM Group achieved Group revenues of 329.6 million (prior year: 297.7 million) and a Group EBITDA of 28.9 million (prior year: 32.6 million).
  • The largest contribution to the CANCOM Group's revenue growth in the third quarter of 2022 came from the IT Solutions business segment.
  • Revenue in the third quarter of 2022 amounted to 69.2 million (prior year: 63.0 million), representing a year-on-year increase of 9.9 percent.

EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022

Retrieved on: 
Friday, November 11, 2022
Investor, CET, Risk, Webcast, Communication, EST, GMT, Q&A, FSE, Management, Annual report, NASDAQ, U.S. Securities and Exchange Commission, Cancer, Clinical trial, Conference, Patient, Judgement, Industry, Video game, Risk management, Pharmaceutical industry, MorphoSys

Invitation to MorphoSys Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022

Key Points: 
  • Invitation to MorphoSys Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
    The issuer is solely responsible for the content of this announcement.
  • Invitation to MorphoSys Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
    MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the third quarter and first nine months 2022 results on November 16, 2022 at 10:00 pm CET (9:00 pm GMT; 4:00 pm EST).
  • MorphoSys' Management team will host a conference call and webcast on November 17, 2022 at 2:00 pm CET (1:00 pm GMT; 8:00 am EST) to present the third quarter and first nine months financial results 2022 and provide an outlook for 2022.
  • The conference call will start with a presentation by the Management team followed by a Q&A session.

EQS-News: STEMMER IMAGING with further improved profitability ratios. EBITDA up 50% – 2022 earnings forecast raised

Retrieved on: 
Friday, November 11, 2022
Blox, Investor, Federal Executive Boards, CVB, Technology, Solution, VDMA, EBITDA, Sport, Growth, EUR, Board of directors, Video game

STEMMER IMAGING generated revenueof EUR 113.0 million in the first nine months, a significant increase of 15.4% year-on-year (9M 2021: EUR 97.9 million).

Key Points: 
  • STEMMER IMAGING generated revenueof EUR 113.0 million in the first nine months, a significant increase of 15.4% year-on-year (9M 2021: EUR 97.9 million).
  • STEMMER IMAGING also confirms its mid-term guidance until 2024 with revenue of EUR 200 million and an EBITDA margin of 13-16%.
  • The nine-month report of STEMMER IMAGING AG as of September 30, 2022, is available for download at www.stemmer-imaging.com in the Investors section.
  • With a high level of expertise and value-added services STEMMER IMAGING additionally offers pre-configured subsystems dedicated to specific applications.

Leading Philanthropies Commit Half a Billion for an Equitable Energy Transition

Retrieved on: 
Friday, November 11, 2022
International Resource Panel, Investment, Leadership, Partnership, Hand, Face, Solution, UNEP, Environment, Climate change, Government, CEO, Global South, Investor, Renewable energy

SHARM EL-SHEIKH, Egypt, Nov. 10, 2022 /PRNewswire/ -- A coalition of leading climate philanthropies today announced an investment of $500 million over the next three years to accelerate a just and equitable energy transition in low and middle income countries, while boosting sustainable development and creating new economic opportunities.

Key Points: 
  • This catalytic philanthropic support will assist efforts by governments alongside civil society organizations and others that give momentum to new and emerging energy transition plans in the Global South.
  • "The world needs southern leadership to prove that development priorities and climate priorities go hand in hand and build precedents for a truly just and equitable clean energy transition."
  • "This funding is intended to support countries to implement their ambitious, just and equitable clean energy agendas," said Christie Ulman, President of Sequoia Climate Foundation.
  • Another key priority for philanthropies is to scale civil society efforts as they continue to be driving forces for a just transition.

IntelGenx Reschedules Third Quarter 2022 Conference Call Due to Technical Issues Experienced Today by Webcast Vendor

Retrieved on: 
Thursday, November 10, 2022
Investor, Risk, Annual report, Securities Act of 1933, R, IP, Webcast, U.S. Securities and Exchange Commission, Securities Exchange Act of 1934, Company, Form 10-K, Patient, Physician, Drug Quality and Security Act

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

Key Points: 
  • IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.
  • IntelGenxs superior film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allow for next generation pharmaceutical products that address unmet medical needs.
  • IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services.
  • IntelGenx assumes no obligation to update any such forward-looking statements.